Literature DB >> 25931899

The evaluation of gallstone formation in patients undergoing Roux-en-Y gastric bypass due to morbid obesity.

Metin Karadeniz1, Mehmet Görgün2, Cemal Kara1.   

Abstract

OBJECTIVE: This study aimed to evaluate gallstone formation, prophylactic and selective cholecystectomy and the effectiveness of ursodeoxycholic acid treatment following laparoscopic Roux-en-Y gastric bypass (LRYGB) in morbid obese patients.
MATERIAL AND METHODS: Files of 60 patients who underwent LRYGB between October 2006 and March 2011 were retrospectively reviewed. Patients were evaluated for formation of gallstones.
RESULTS: Fifty-three (88.3%) patients were female and seven (11.7%) were male. Eight of the 60 patients (13.3%) had previously undergone cholecystectomy. Six patients (11.5%) underwent cholecystectomy in addition to LRYGB due to preoperatively detected gallstones by ultrasonography. The remaining 46 patients were followed up for a mean duration of 28.57 months (5-56 months). In 10 (21.7%) of these patients, gallstones were detected and five patients with symptomatic gallstones underwent cholecystectomy. Patients who did and did not develop gallstones after LRYGB did not show a significant difference regarding age, gender and the new body mass index (BMI). Three patients were started on ursodeoxycholic acid and the treatment was continued for six months. Gallstones were not detected in these patients.
CONCLUSION: In light of these data, since only a very small portion of patients develops symptomatic gallstones after LRYGB, we recommend cholecystectomy in patients with symptomatic gallstones or the use of ursodeoxycholic acid rather than a prophylactic approach. Prospective randomized controlled studies in larger series are required to support these results.

Entities:  

Keywords:  Obesity; gallstones; laparoscopic gastric bypass

Year:  2014        PMID: 25931899      PMCID: PMC4379817          DOI: 10.5152/UCD.2014.2538

Source DB:  PubMed          Journal:  Ulus Cerrahi Derg        ISSN: 1300-0705


  23 in total

1.  Is routine cholecystectomy necessary at the time of Roux-en-Y gastric bypass?

Authors:  Jerome Taylor; I Michael Leitman; Michael Horowitz
Journal:  Obes Surg       Date:  2006-06       Impact factor: 4.129

2.  The case for prophylactic cholecystectomy concomitant with gastric restriction for morbid obesity.

Authors:  J H Schmidt; M P Hocking; W R Rout; E R Woodward
Journal:  Am Surg       Date:  1988-05       Impact factor: 0.688

Review 3.  Hepatobiliary effects of obesity and weight-reducing surgery.

Authors:  W W Faloon
Journal:  Semin Liver Dis       Date:  1988-08       Impact factor: 6.115

4.  Is prophylactic cholecystectomy useful in obese patients undergoing gastric bypass?

Authors:  Héctor Guadalajara; Raquel Sanz Baro; Isabel Pascual; Isabel Blesa; Grevelyn Sosa Rotundo; Jose María Gil López; Ramón Corripio; Gregorio Vesperinas; Luis García Sancho; Jose Antonio Rodríguez Montes
Journal:  Obes Surg       Date:  2006-07       Impact factor: 4.129

5.  Impact of rapid weight reduction on risk of cholelithiasis after bariatric surgery.

Authors:  Carlos Iglézias Brandão de Oliveira; Elinton Adami Chaim; Benedito Borges da Silva
Journal:  Obes Surg       Date:  2003-08       Impact factor: 4.129

6.  Gallbladder kinetics in obese patients. Effect of a regular meal and low-calorie meal.

Authors:  L Marzio; F Capone; M Neri; A Mezzetti; C De Angelis; F Cuccurullo
Journal:  Dig Dis Sci       Date:  1988-01       Impact factor: 3.199

7.  Almost routine prophylactic cholecystectomy during laparoscopic gastric bypass is safe.

Authors:  A Nougou; M Suter
Journal:  Obes Surg       Date:  2008-05       Impact factor: 4.129

8.  Gallstone formation after rapid weight loss: a prospective study in patients undergoing gastric bypass surgery for treatment of morbid obesity.

Authors:  M L Shiffman; H J Sugerman; J M Kellum; W H Brewer; E W Moore
Journal:  Am J Gastroenterol       Date:  1991-08       Impact factor: 10.864

Review 9.  Clinical application of laparoscopic bariatric surgery: an evidence-based review.

Authors:  Timothy M Farrell; Stephen P Haggerty; D Wayne Overby; Geoffrey P Kohn; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2009-01-06       Impact factor: 4.584

10.  Routine preoperative ultrasonography and selective cholecystectomy in laparoscopic Roux-en-Y gastric bypass. Why not?

Authors:  Alex Escalona; Camilo Boza; Rodrigo Muñoz; Gustavo Pérez; Sabina Rayo; Fernando Crovari; Luis Ibáñez; Sergio Guzmán
Journal:  Obes Surg       Date:  2007-12-15       Impact factor: 4.129

View more
  5 in total

1.  A Prospective Study of the Conservative Management of Asymptomatic Preoperative and Postoperative Gallbladder Disease in Bariatric Surgery.

Authors:  Omar Pineda; Hernán G Maydón; Mónica Amado; Elisa M Sepúlveda; Lizbeth Guilbert; Omar Espinosa; Carlos Zerrweck
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

Review 2.  Abdominal Pain in the Roux-en-Y Gastric Bypass Patient.

Authors:  Allison R Schulman; Christopher C Thompson
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

3.  Bariatric Surgery Did Not Increase the Risk of Gallstone Disease in Obese Patients: a Comprehensive Cohort Study.

Authors:  Jian-Han Chen; Ming-Shian Tsai; Chung-Yen Chen; Hui-Ming Lee; Chi-Fu Cheng; Yu-Ting Chiu; Wen-Yao Yin; Cheng-Hung Lee
Journal:  Obes Surg       Date:  2019-02       Impact factor: 4.129

4.  Incidence of Symptomatic Cholelithiasis Following Laparoscopic Roux-en-Y Gastric Bypass Is Comparable to Laparoscopic Sleeve Gastrectomy: A Cohort Study.

Authors:  Mahdieh Golzarand; Karamollah Toolabi; Reza Parsaei; Sina Eskandari Delfan
Journal:  Dig Dis Sci       Date:  2021-11-16       Impact factor: 3.487

5.  Increased Incidence of Symptomatic Cholelithiasis After Bariatric Roux-En-Y Gastric Bypass and Previous Bariatric Surgery: a Single Center Experience.

Authors:  Midhat Abu Sneineh; Lotem Harel; Ahmad Elnasasra; Hadas Razin; Assaf Rotmensh; Sharon Moscovici; Hasan Kais; Haim Shirin
Journal:  Obes Surg       Date:  2020-03       Impact factor: 4.129

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.